Table 6.
Received treatment according to study groups.
| Characteristics | Study groups | |||
|---|---|---|---|---|
| CE-CT (n = 144) | FDG-PET/CT(n = 83) | Combined (n = 73) | p-value | |
| Number of treatment lines | <0.001 | |||
| Mean ± standard deviation | 3.1 ± 1.6 | 2.5 ± 1.5 | 3.6 ± 2.0 | |
| Median (interquartile range) | 3 (1–8) | 2 (0–8) | 3 (1–9) | |
| Duration of treatment courses (months) | 0.01 | |||
| Mean ± standard deviation | 10.3 ± 9.5 | 13.9 ± 14.5 | 15.9 ± 15.9 | |
| Median (interquartile range) | 6.8 (0.50–49.3) | 7.7 (0.50–76.7) | 9.3 (1.4–105) | |
| Time to first treatment changea (months) | 0.03 | |||
| Mean ± standard deviation | 17.6 ± 13.5 | 12.9 ± 11.6 | 16.0 ± 15.3 | |
| Median (interquartile range) | 13.6 (2.4–61.7) | 10.1 (1.8–61.3) | 11.4 (1.5–77.1) | |
| Time to detect second progressionb (months) | <0.001 | |||
| Mean ± standard deviation | 8.1 ± 7.9 | 12.1 ± 8.1 | 14.7 ± 15.8 | |
| Median (interquartile range) | 5.6 (1–42.7) | 10.4 (2.8–33.5) | 11 (1.6–106.2) | |
| Time period receiving treatment (months) | <0.001 | |||
| Mean ± standard deviation | 26.7 ± 20.1 | 27.0 ± 23.8 | 43.5 ± 31.2 | |
| Median (interquartile range) | 22.2 (0.9–84.8) | 19.3 (0–112.6) | 33.5 (2.8–135.3) | |
| Time period receiving chemotherapy (months) | 0.005 | |||
| Mean ± standard deviation | 12.6 ± 11.6 | 8.9 ± 7.2 | 19.2 ± 20.7 | |
| Median (interquartile range) | 8.6 (0.1–61.9) | 7.2 (0.2–26.9) | 12.5 (0.1–123.9) | |
CE-CT contrast-enhanced computed tomography, FDG-PET/CT Fluorodeoxyglucose positron emission tomography with integrated computed tomography.
aTime period between baseline scan and first detected progression leading treatment change.
bTime period between first and second detected progressions leading treatment change.
Statistically significant p < 0.05 values are in bold.